-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GFusFTefxZtUGw1aAzRXrIUWdAS8Td5ZKTkgnV6VFv/4rWpA+IXgiQ4eXpgaDXPk
 6StzzEQ2932QKbh8uY6i/g==

<SEC-DOCUMENT>0000891020-06-000014.txt : 20060119
<SEC-HEADER>0000891020-06-000014.hdr.sgml : 20060119
<ACCEPTANCE-DATETIME>20060119171732
ACCESSION NUMBER:		0000891020-06-000014
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20050822
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20060119
DATE AS OF CHANGE:		20060119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TARGETED GENETICS CORP /WA/
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23930
		FILM NUMBER:		06538883

	BUSINESS ADDRESS:	
		STREET 1:		1100 OLIVE WAY
		STREET 2:		STE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
		BUSINESS PHONE:		2066237612

	MAIL ADDRESS:	
		STREET 1:		1100 OLIVE WAY
		STREET 2:		STE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>v16333e8vkza.htm
<DESCRIPTION>AMENDMENT TO FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Amendment to Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>






<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549<BR>
___________</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K/A<BR>
CURRENT REPORT</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">Date of Report (Date of earliest event reported)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>August&nbsp;22, 2005</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 18pt"><B>Targeted Genetics Corporation</B>
</DIV>


<DIV align="center">
<DIV style="font-size: 3pt; margin-top: 2pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 1pt">(Exact name of registrant as specified in its charter)
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Washington</B></TD>

<TD nowrap align="center" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>0-23930</B></TD>
<TD nowrap align="center" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>91-1549568</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction<BR>
of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File<BR>
Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="67%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="27%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>1100 Olive Way, Suite 100, Seattle, Washington</B></TD>
<TD nowrap align="left" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>98101</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">Registrant&#146;s telephone number, including area code
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(206)&nbsp;623-7612</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Not Applicable</B>
</DIV>


<DIV align="center">
<DIV style="font-size: 3pt; margin-top: 2pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 2pt">(Former name or former address if changed since last report)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
</DIV>

<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="97%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>
</TABLE>
</DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="97%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>
</TABLE>
</DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="97%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))</TD>
</TR>
</TABLE>
</DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="97%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))</TD>
</TR>
</TABLE>
</DIV>



<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>



</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">







<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Item&nbsp;5.02.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><u>Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.</u></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;22, 2005, Targeted Genetics Corporation filed a current report on Form 8-K announcing,
among other things, the appointment of David J. Poston as Acting Chief Financial Officer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On January&nbsp;18, 2006, Targeted Genetics Corporation announced that Mr.&nbsp;Poston had been
appointed Vice President, Finance, Chief Financial Officer and Treasurer. A press release
announcing Mr.&nbsp;Poston&#146;s permanent appointment is attached as Exhibit&nbsp;99.1 to this amended current
report and is incorporated herein by reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U><B>Financial Statements and Exhibits</B></U><B>.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">(c)&nbsp;&nbsp;&nbsp;Exhibits
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="86%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Exhibits:</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Description of Document</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">99.1
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release dated January&nbsp;18, 2006</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>

<TD colspan="3" align="left"><FONT style="font-variant: small-caps">Targeted
Genetics Corporation</FONT><br>&nbsp;<br>&nbsp;<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/&nbsp;<FONT style="font-variant: small-caps">H. Stewart Parker</FONT>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">H. Stewart Parker&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">President and Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dated: January&nbsp;19, 2006
</DIV>


<P align="center" style="font-size: 10pt">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT INDEX</U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="95%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Exhibits:</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Description of Document</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">99.1
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release dated January&nbsp;18, 2006</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">4
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v16333exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">



<DIV align="right" style="font-size: 10pt; margin-top: 6pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="v16333v1633300.gif" alt="LOGO">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Investor and Media Contact:</B><BR>
Stacie D. Byars<BR>
Director, Communications<BR>
Targeted Genetics Corporation<BR>
(206)&nbsp;521-7392

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TARGETED GENETICS APPOINTS DAVID J. POSTON AS CHIEF FINANCIAL OFFICER</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Seattle, WA </B>&#151; January&nbsp;18, 2006 &#151; Targeted Genetics Corporation (Nasdaq: TGEN) announced today the
appointment of David&nbsp;J. Poston as Vice President, Finance, Chief Financial Officer, and Treasurer.
Mr.&nbsp;Poston has been serving as the acting Chief Financial Officer at Targeted Genetics since
October&nbsp;2005 and has been a key part of the company&#146;s finance organization since January&nbsp;1999.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;David has made significant contributions to our progress during his seven years with the company
and his more than twenty years of financial experience make him a natural choice as CFO,&#148; said H.
Stewart Parker, President and Chief Executive Officer of Targeted Genetics. &#147;Having David as a
tenured financial resource to the management team is extremely important as we continue to advance
our product pipeline, enter into strategic collaborations and consider capital-raising
opportunities.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">David J. Poston, 42, previously served as the company&#146;s senior director of finance and accounting
from 2001 through 2005 and as the finance director from 1999 to 2001. Prior to joining Targeted
Genetics, he served as controller of Corixa Corporation, controller and assistant treasurer of Todd
Shipyards Corporation and in financial management capacities at Rocket Research Corporation (now
General Dynamics). Mr.&nbsp;Poston has over twenty years of financial experience, has had primary
responsibility for public company financial disclosure matters since 1993 and started his career in
public accounting at KPMG in 1985. Mr.&nbsp;Poston graduated from the University of Puget Sound with a
B.S. in accounting, a minor in mathematics and as the Norton Clapp Arete Scholar.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About Targeted Genetics</B>
</DIV>


<DIV align="left" style="font-size: 10pt">Targeted Genetics Corporation is a biotechnology company committed to the development and
commercialization of innovative targeted molecular therapies for the prevention and treatment of
inflammatory arthritis, HIV/AIDS and other acquired and inherited diseases with significant unmet
medical need. Targeted Genetics uses its considerable knowledge and capabilities in the development
and manufacturing of gene delivery technologies to advance a diverse product development pipeline.
Its product development efforts target inflammatory arthritis, HIV/AIDS, congestive heart failure,
Huntington&#146;s disease, and hyperlipidemia. To learn more about Targeted Genetics, visit its website
at www.targetedgenetics.com.</DIV>




</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">



<DIV align="left" style="font-size: 9pt; margin-top: 6pt"><B><I>Safe Harbor Statement
under the Private Securities Litigation Reform Act of 1995:</I></B><BR>
<I>This release contains forward-looking statements regarding our business strategy, our product
development, our personnel and other statements about our plans, objectives, intentions and
expectations. In particular, the statements regarding the Company&#146;s future plans are
forward-looking statements. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts.
Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of
forward-looking statements. Factors that could affect our actual results include, but are not
limited to, the timing, nature and results of our clinical trials, potential development of
alternative technologies or more effective products by competitors, our ability to obtain and
maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our
intellectual property and our ability to raise capital when needed, as well as other risk factors
described in the section entitled &#147;Factors Affecting Our Operating Results, Our Business and Our
Stock Price&#148; in our Quarterly Report on Form&nbsp;10-Q for the period ended September&nbsp;30, 2005. You
should not rely unduly on these forward-looking statements, which apply only as of the date of this
release. We undertake no duty to publicly announce or report revisions to these statements as new
information becomes available that may change our expectations.</I>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I># # #</I>
</DIV>



</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>v16333v1633300.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v16333v1633300.gif
M1TE&.#EAAP"=`.8``!04%%%14>[N[G)R<O3T]'U]?555569F9EM;6ZJJJF)B
M8H&!@<3$Q.#@X)Z>GBPL+$1$1&!@8'1T=.;FYFIJ:D%!00$!`8B(B,#`P-[>
MWJ2DI+R\O*ZNKM34U"<G)Y65E4U-3>3DY%U=7<?'QQX>'J*BHDE)2;JZNKZ^
MOM#0T#T]/<G)R9R<G,W-S3@X.+2TM#4U-0D)"86%A8*"@GAX>#$Q,6]O;]+2
MTI*2DG!P<'IZ>C0T-*RLK`T-#79V=B$A(5=75Y:6EAP<'+*RLCL[.T='1QD9
M&>OKZ_S\_/O[^_+R\NCHZ*&AH6EI:?[^_L+"PMG9V8Z.CMK:VOCX^&QL;+"P
ML)N;FZ>GIXV-C>WM[<O+RY"0D-;6UO;V]N+BXHJ*BMW=W?KZ^O'Q\8R,C,[.
MSI&1D8>'A]S<W(N+BVUM;?W]_>KJZOGY^=?7U^SL[/?W]\/#P]O;V^/CX_#P
M\+&QL<K*RK>WMYJ:FJ:FIL_/S_/S\^GIZ6AH:*"@H(^/C____R'Y!```````
M+`````"'`)T```?_@'\34(2%AH>(B8J+C(V.CY".>W^4E9:78D4*FYR=GI^@
MH:*CI*6FIZ01.4F7K95+!TBNL[2UMK>XN;J[:GU*N4M-:KO$Q<;'R)9.);^X
MP:S)T=+3QTA,S;?/M]"73M3?X+C6V+;:MBD&-#0%.C1I=^'Q\I;CP$W<M'DQ
M^Q86,18Z6M5Q,*(5FR$./GPH<6;6""PRJF1A8ZF#`RL*H]BQI&7+!Q8L/I3A
M8NF)@SL*MZRP1.!*0BL;9-VJY^S>K3D-E-RP@$!)E@FMTE@XT$K-``LU:L0`
M\*(5%0L/*ECPD,$2!@L]8.SX,<,2$P\[_.UXL+&2`PM&M'I@8BE)#:0`_RP$
MP#>+9C:;N1I84#!KB1$2`(!>*A"#P!\&/"_=L;!`%IXOET98L$%IBAM+`KH@
M<5$$R1MR"2S`^_-9&0PB28YHL`#9EMUR>'&!L1!A5@(`=&+@:45X1(<2%@98
M4@.#1!>*KB0'P&!GR2P5)ER%'H#A1)AN,%14JO!@6*W7M<S)ICU+@78/(%HM
MZ->O@AQ+4X08^/,"B`P9'2Q)]F?AQ"PBT;42FC\`'(&==I0`00)RM(!'BWBW
MS%9;40\\\,4/%C1D20$66&$"`"%<DH0'-?R!`@1&6("!?CQU`(=@K0`H'4`N
MOG%@)2!X0%<K#O85VRT9[.4*'0`44(`/%N`P6/\,?X@!``*M'-4')4<]P:)P
ME7ASB8P"6N!`EJ8AR$`,5,QTC3T[TM*&!?-U4P0,E9``@9:4Y&"!`'\<I<4E
M`DAE`@(]]%!'218`8(()1=A`)R5./(#@):MY<"@$8PSWE@DN(.6<:V?6E.8L
M=1R`!EUAT/!!)5M(8",E;.#`QR0,*,`6GU$$``(-9%RRP@$*(."K#MY50H`.
M,LAD214'1.`K$*=6HD<!O2IP`8S?=7K7I]+0N>@WVVZKB[?B6`L;MO.4:ZXK
M/;H"X;GLMEM)NJVLZ\H30;!@Q;WXYJOOOOSVZ^^_``?,+PM!;&`F.>'].$L!
M#M!1Q<,01RSQQ!17;/'_Q1AG3#$=901P,)JW^&&8NR33(@<"X-(C;L+D4A*%
M@27'?(D4*'.*\(,*N_*RS#Q30G/*[ZZ,<\M_[-RSS#_;#+(M1D\#QQT.1"WU
MU%17[0"U\B1=[<T^$MUT,A@@\`][9)=M-MDUK%2NU@T*W?4M7Q]3Q]ETU\T>
M"2VL7?/62]<2=S%3`+'/X(07;OCA4PV:]=YM<ZUNSJW\34P84(!A^>689Z[Y
MYFUX,0_;=;G]N-<P'UTRZ.B*'B_DETANNKFH\ZCZ)?)&7KHQ#3"AP>Z\]^[[
M[\`'7\*FT<1^";RTLVZ)Z[C``4,,@48O_?345V]]#S&8$&+QC(?N^.JD(W-`
M_Z$`E&_^^>BGK_[Z<54P23+&J_Q]\N$?\P3[^.>/?PP08$U,_$&;GR5JU[K;
M%2,%*]""`A?(P`8Z\($07.`3B&<,`%(">0-47B68][K%`>V"L\M@_3K8+@O^
M`8.OT*#+#&B,%%S`#UN(H0QG2,,:VO"&,<1"$"BH"Q.BD!($7!X+B^&%!P"`
M!$A,HA*7R,0F.C&)0E`!"XKAPQ"F<(3)L$,-?N"!+GKQBV`,HQC'Z$4`4.9_
MW4N=`*\(MR$:`P,5@($+YDC'.MKQCGC,XQQKT!0T?O"$5@2B"HOF1F,0P`U9
M2*0B%\G(1CKRD8HT5@_3*+LU"A*+)(0=)8\7R#\$<?^#A<PD.*IH24\.DH/3
M2(`$9K"`5KKRE;",I2P7X#DJ;E)^?:,%*J4!!A$\0(_`S",,8-"`"MXR@+F<
MQ2ZEL0<$$*$"T(RF-*=)S6FZ8`8,V@4IDZFS4'YC!$6`@#C'2<YRFI.<%9C!
M=8SYQQ^:$I/EFH`4SD#/>MKSGOBT9[!LV<Y.?G*%HF37-CW5QH">:Z#7*NCK
M&O""#3CTH1`]`0:R>0R$CDNAIEL##4`0@(YZU*,F8,(^*WI,$);RGX0DX1L6
M``(#N/2E!@C`!=;)O7Z>])3>))D`9*"``_CTITUXSS0LRC*,=E`->B"`4I?:
MA6\0=6A&-6@\GOHVIN54JLC_H.KHHHI5IY84D#>%9U>'^E5WHG298_6CT@AJ
MU0YZH0%PC:M<YRI4DMJ4F[8SG1XXD(,!^/6O@`WL``IBU[4FM*T]PT`!TB#8
MQ@+6!@F0Y"3ORE:_734<3IB``YK`AS1X]K.@#>UGJ:``/-!TLH:]*&)+IH8.
M;``.#(BM;&=+6]H^`0-X4BO?*JO+RZ85M;L]K&5_.\JR^A.G)'."&);+W.8Z
M][G0'9DVC1M6KLXC!'C80AFVR]WN>O>[WHT"$X@V,^KBM8#M>H@9T,#>]KKW
MO?!][P5FH`')WD*KX+/N-]3`!0W,0`9F"+"`!TS@`A-8!CA@0%-UV[CS"M%<
M76C!_PA:0(8*6_C"&,XPAEO0@LNP,[5%72UQI8%?^NEWQ/P$,51%_(TD$*`+
M,(ZQC&=,XQIW@0!*&"F#O>=@4&(6"B_@`0>&3.0B&_G(2.9``CI@W^E25KB]
M!<<<GK"[*UCYREC.LI:W?`4FY*VF*J[J<*>1A#@DH`1<3K.:K8P'/(R@R3M6
M8X\!.@T]P-4+>,ZSGO?,YS[CN0'^*VQP53MF%(-YT"$NM*&S:E[>*M.W\%G#
M$29-Z4I;^M*8GO0$2BGH!CNZF\1X@T70@(52F_K4J$ZUJK%@ACL$VJM/)G24
M=U&'&5Q@#+C.M:YWS>M>CT$&"1##01L-Y4<3HPT`OH"RE__-[&8[^]DRT,"J
M-!GK1,]:%P1(01Y2P.UN>_O;X`;WMJ5+[3!OE<6+3C&B5ZSH=*O;T\4&M3'6
ML(0UV/O>^%[#!*80T!*+\,2V8,``?*".@AO<!M+N-[%E;>QC<*`)CCU`"2C:
M07^S$=VZL,8!*$"%CE.!`FG@P;1%:?%+`OP6!$`!!E:^\@U\6:HE?^?)W5V+
MF)\5TC2WA,V1F_-W\_C3>>UYG"LYYY0*W<GFSB_&CTZ+G8MU%UJXP*I7/08L
M%!-I"[=VP^6&@(]Z_>L>!4$:>%C"K+/[VL5@0`0"`-.VNQVF(+#!J_56[;-O
MG1AQD(`-),#WOOO][X"G@`/X33+_I\]\%F]X0Q@6S_C&._[QBR>`CLN];C&C
MG>FV,/S2,=\*S;=[&QJ0P1=&3_K2F_[TJ"]]M.F>=!-O?A8;V($<@TE[8<*@
M!)\SN^7OC@L[P*":P`^^\%6@@CQXL/7_?KTKIJ`#%9SS^="/O@H,</7BUGWW
M\MX%`3K0`2YX__O@#[_XQR_^/,R=T=<_]^<Y[PK/7Y[][=>]^M^/"S8XP`]!
M4(C^]\___OO___MW!VMP:/#&<-FW"T[@`$;P%T_4@`[H1$80`.=W7_*G=.N7
M"U?P`P^X@1P(&$0`!>B'?!=W@;G@`'L'>"B8@BJH@A30!^05?^EG@?275D[P
M1TU7@:Y'_X+PYS,XF'PZR`O$Y7Z\APQ@H``1@`I("`I'6'VY((0'F`QL$`'^
M<#A46(562#@6T!5(5WGS-X3((`<J,(57.(9D2`16LH4%J'5/&`U<(`)'F(1)
M*`(#D%MH^'/Q%G0[.`M.B(=YV'D].((S2#)3P`9(4(B&>(B'F`1(8(,W&(,Y
M&(CN0@:U5T<OYW-R!G3H93IJ\!1V4S9G^&%<*(->&#-S\!:=V`\N0&Y#QTG5
MI7SN`@:L-$NN)`-5$8*A^(BCV(=[>`E^0(=]>`E@\(<F9PLRT`9ND&G(F(S*
MN(S,V(R9Y@8C$`".Z(.T@`,*D`8>EXW:N(W<V(W>^(W@&([?F/\&"K``'X.)
MRL`&4[".[-B.[OB.\!B/\CB/]%B/\GA::6AWOQ@/9C5(^Y@,_?B"?T`&=X`%
M=,!IOQB0XL`'9/,`'+`H#8`!MU4=A%4)2@`'3S`'@H`"3/@'$3F1)U"1E$`&
M&X`!&(D!+Z"1PL(`&!!H<O`"=J"2E\`&&%`%<+!@(CB,MH`#%F`"&]`&,P``
MGT@)B`$]V,,7EC`!/6`!!H,8N\$B1AD#1&$)%,`/T!,#&D()86`").!AEI``
M0H`]#[`BEB`'$-`#)!`#1-`&YWB'EQ`',0`"QE*+E@`%;!('<<!]?!(7'M,!
M%D`'EV"7!H"7>FD)7-`!=1`#-B`%<"#_DY2``!XP4GU@`7S@!5!0`0:S(1;0
M`E.``0>`D_F(?5V">W*@!Y4A26O"!XS2"ED``$3PEWI1!9>0FI0P>7_0!3%P
M`;,`F?C@!"K0`\+V!VLP4C1@`1*P/>'2BK6P&#SP!U9``CN@`C1`;FT`/0_P
M`T/`FC$0!#DR)K)I"=79`]>9`+,@`#$@`[NI(Y;`!B20'K00!P'P#Q[@`^]3
M>0(@!;Z(4B]@`6CP!W9P`$!@`10PFTA1`!*0*Y>0!3'@`"O0DST`F.!9H`.@
M-JU@GNCI"KRYGC]0`;?0`+5B`4!0;6RP!4"```;P!:N"4A-@!$)`$G\@!T-!
MH!*@#):@H$HB_P+]T$>5L"8S"B9\<I[IV9LF8`$I0`D<T)%'4'T5\`-PADR5
M,`42L`!0$`<-<`$#8",H]0=7$0-`<`!AD0.!B10+8"11@`\"D"3"B2$Z2@EV
M60-CJ@-CL"-*`*08Z@&MH`4`\`-?,`,6``*@*0,`,`!!8`,Q0`-M^0=]<*4*
M4`8'@`(Z\"59^@<;(!5H@0..*:D`L)3_X`*2=`9%0@D%T`/D:0D;D*G\`0/V
M=0-FY`IS4`0>(`6M,`(PT`\'D`>2M`$!T`\QL`#X>(E_D`04@&?PX)E[0`5)
M$*F4``9<P#5*X`8"\*QNX`629!FYU:RJV*S/*@!NT`#V10!'X(N5P+@&]F::
MK1`&;4"7K3`!'7!9=K$$(*`&2X``6#``'/`'(+`$R/J/Q6`7;A``:A`".E`&
M9<(&`>`&P="D^AH-:F`M3C``YH<%?Y`#9-`!$I!939"PY<(,EL``)B``13H!
M0P`"</`'`@`!&T<!*)NR*KNR+-NR+ONR,!NS,CNS-/NR!V`#^,@$!L``$S`"
M(O`E?^`$'?`$1%NT1GNT2)NT2KNT3-NT3ONT4-NT&`""K?`",U``"_"=?Q`(
"`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
